Logo FUNDABETS
Home
Candlestick Pattern Screener Chart Pattern Screener Custom Screener
Contact Us
Your Profile Settings Sign out
Home Candlestick Pattern Screener Chart Pattern Screener Custom Screener Contact Us
Tom Cook
tom@example.com
Your Profile Settings Sign out

Global Stocks Search

Help with searching

Search our entire platform for stocks by symbol, name, or exchange.

Navidea Biopharmaceuticals, Inc. (NAVB)

USD 0.0

(16.67%)

Overview Income Statements Balance Sheets Cash Flows Historical Prices Other

Revenue Summary of Navidea Biopharmaceuticals, Inc.

  • Navidea Biopharmaceuticals, Inc.'s latest annual revenue in 2022 was 65.65 Thousand USD , down -87.65% from previous year.
  • Navidea Biopharmaceuticals, Inc.'s latest quarterly revenue in 2023 Q3 was - USD , down 0.0% from previous quarter.
  • Navidea Biopharmaceuticals, Inc. reported a annual revenue of 531.51 Thousand USD in annual revenue 2021, down -41.91% from previous year.
  • Navidea Biopharmaceuticals, Inc. reported a annual revenue of 915.01 Thousand USD in annual revenue 2020, up 3337.57% from previous year.
  • Navidea Biopharmaceuticals, Inc. reported a quarterly revenue of - USD for 2023 Q1, down -100.0% from previous quarter.
  • Navidea Biopharmaceuticals, Inc. reported a quarterly revenue of - USD for 2023 Q3, down 0.0% from previous quarter.

Annual Revenue Chart of Navidea Biopharmaceuticals, Inc. (2022 - 1992)

Historical Annual Revenue of Navidea Biopharmaceuticals, Inc. (2022 - 1992)

Year Revenue Revenue Growth
2022 65.65 Thousand USD -87.65%
2021 531.51 Thousand USD -41.91%
2020 915.01 Thousand USD 3337.57%
2019 26.61 Thousand USD -91.75%
2018 322.52 Thousand USD -82.19%
2017 1.81 Million USD -91.76%
2016 21.96 Million USD 65.82%
2015 13.24 Million USD 111.15%
2014 6.27 Million USD 454.99%
2013 1.13 Million USD 1335.94%
2012 78.73 Thousand USD -86.83%
2011 597.72 Thousand USD -94.41%
2010 10.7 Million USD 12.42%
2009 9.51 Million USD 20.69%
2008 7.88 Million USD 10.69%
2007 7.12 Million USD 17.74%
2006 6.05 Million USD 2.22%
2005 5.91 Million USD -0.56%
2004 5.95 Million USD -8.56%
2003 6.5 Million USD 32.29%
2002 4.92 Million USD -35.11%
2001 7.58 Million USD -21.9%
2000 9.71 Million USD 2.8%
1999 9.44 Million USD 61.94%
1998 5.83 Million USD 13.74%
1997 5.12 Million USD 337.84%
1996 1.17 Million USD 17.12%
1995 1 Million USD 11.11%
1994 900 Thousand USD 800.0%
1993 100 Thousand USD 0.0%
1992 100 Thousand USD 0.0%
Year Revenue Revenue Growth
2023 Q2 - USD 0.0%
2023 Q1 - USD -100.0%
2023 Q3 - USD 0.0%
2022 Q3 7516.00 USD 15.29%
2022 Q4 610.00 USD -91.88%
2022 FY 65.65 Thousand USD -87.65%
2022 Q1 - USD -100.0%
2022 Q2 6519.00 USD 0.0%
2021 Q3 96.38 Thousand USD -63.08%
2021 Q4 50.34 Thousand USD -47.76%
2021 Q2 261.04 Thousand USD 110.97%
2021 FY 531.51 Thousand USD -41.91%
2021 Q1 123.73 Thousand USD -43.56%
2020 Q4 219.25 Thousand USD 3137.13%
2020 FY 915.01 Thousand USD 3337.57%
2020 Q1 15.22 Thousand USD 467.95%
2020 Q2 8920.00 USD -41.4%
2020 Q3 6773.00 USD -24.07%
2019 Q1 97.55 Thousand USD 178.42%
2019 FY 26.61 Thousand USD -91.75%
2019 Q4 2680.00 USD -45.25%
2019 Q3 4895.00 USD -69.2%
2019 Q2 15.89 Thousand USD -83.71%
2018 FY 322.52 Thousand USD -82.19%
2018 Q4 35.04 Thousand USD 57.05%
2018 Q3 22.31 Thousand USD -91.56%
2018 Q2 264.37 Thousand USD 33154.59%
2018 Q1 795.00 USD -99.8%
2017 Q3 223.66 Thousand USD -63.43%
2017 Q4 395.13 Thousand USD 76.66%
2017 Q2 611.59 Thousand USD 5.44%
2017 FY 1.81 Million USD -91.76%
2017 Q1 580.03 Thousand USD -82.71%
2016 Q2 5.39 Million USD 14.23%
2016 FY 21.96 Million USD 65.82%
2016 Q4 3.35 Million USD -60.51%
2016 Q3 8.49 Million USD 57.51%
2016 Q1 4.72 Million USD 9.99%
2015 FY 13.24 Million USD 111.15%
2015 Q4 4.29 Million USD 7.9%
2015 Q2 2.86 Million USD 36.02%
2015 Q3 3.97 Million USD 38.75%
2015 Q1 2.1 Million USD -4.09%
2014 Q3 2.25 Million USD 109.37%
2014 Q2 1.07 Million USD 42.95%
2014 FY 6.27 Million USD 454.99%
2014 Q1 751.8 Thousand USD 40.53%
2014 Q4 2.19 Million USD -2.3%
2013 FY 1.13 Million USD 1335.94%
2013 Q4 534.97 Thousand USD 33.62%
2013 Q2 195.27 Thousand USD 0.0%
2013 Q3 400.37 Thousand USD 105.03%
2013 Q1 - USD -100.0%
2012 FY 78.73 Thousand USD -86.83%
2012 Q4 6807.00 USD -97.99%
2012 Q3 339 Thousand USD 465.0%
2012 Q2 60 Thousand USD 402.89%
2012 Q1 11.93 Thousand USD 100.19%
2011 Q2 3.19 Million USD 12.56%
2011 FY 597.72 Thousand USD -94.41%
2011 Q4 -6.29 Million USD -2560.84%
2011 Q3 255.63 Thousand USD -92.0%
2011 Q1 2.83 Million USD -10.58%
2010 Q2 2.53 Million USD -5.37%
2010 Q3 2.3 Million USD -9.27%
2010 Q4 3.17 Million USD 37.84%
2010 FY 10.7 Million USD 12.42%
2010 Q1 2.68 Million USD 9.74%
2009 FY 9.51 Million USD 20.69%
2009 Q4 2.44 Million USD -5.5%
2009 Q2 1.83 Million USD -32.71%
2009 Q3 2.58 Million USD 41.08%
2009 Q1 2.72 Million USD 33.05%
2008 Q3 1.8 Million USD -20.17%
2008 Q2 2.25 Million USD 26.49%
2008 Q1 1.78 Million USD -5.12%
2008 Q4 2.04 Million USD 13.77%
2008 FY 7.88 Million USD 10.69%
2007 FY 7.12 Million USD 17.74%
2007 Q4 1.87 Million USD -5.34%
2007 Q3 1.98 Million USD 30.82%
2007 Q2 1.51 Million USD -12.96%
2007 Q1 1.74 Million USD -6.83%
2006 Q1 1.78 Million USD 25.98%
2006 FY 6.05 Million USD 2.22%
2006 Q3 957.95 Thousand USD -33.2%
2006 Q2 1.43 Million USD -19.8%
2006 Q4 1.87 Million USD 95.33%
2005 FY 5.91 Million USD -0.56%
2005 Q2 1.7 Million USD 16.03%
2005 Q4 1.41 Million USD 6.42%
2005 Q3 1.33 Million USD -21.6%
2005 Q1 1.46 Million USD 16.9%
2004 Q1 1.42 Million USD -24.79%
2004 Q2 1.54 Million USD 8.58%
2004 Q3 1.72 Million USD 11.45%
2004 Q4 1.25 Million USD -27.31%
2004 FY 5.95 Million USD -8.56%
2003 Q1 1.53 Million USD -8.14%
2003 FY 6.5 Million USD 32.29%
2003 Q4 1.89 Million USD 59.9%
2003 Q3 1.18 Million USD -37.26%
2003 Q2 1.88 Million USD 22.79%
2002 Q2 1.26 Million USD 19.34%
2002 Q1 1.06 Million USD -44.04%
2002 FY 4.92 Million USD -35.11%
2002 Q4 1.67 Million USD 82.17%
2002 Q3 919.76 Thousand USD -27.31%
2001 Q3 1.79 Million USD -21.3%
2001 FY 7.58 Million USD -21.9%
2001 Q2 2.27 Million USD 40.63%
2001 Q1 1.61 Million USD -42.53%
2001 Q4 1.89 Million USD 5.71%
2000 Q4 2.81 Million USD 21.19%
2000 Q2 2.71 Million USD 46.12%
2000 Q1 1.85 Million USD -56.02%
2000 FY 9.71 Million USD 2.8%
2000 Q3 2.32 Million USD -14.26%
1999 Q3 1.4 Million USD -26.32%
1999 Q2 1.9 Million USD 0.0%
1999 Q4 4.22 Million USD 201.43%
1999 Q1 1.9 Million USD -6.53%
1999 FY 9.44 Million USD 61.94%
1998 Q4 2.03 Million USD 19.57%
1998 Q1 900 Thousand USD -44.71%
1998 FY 5.83 Million USD 13.74%
1998 Q2 1.3 Million USD 44.44%
1998 Q3 1.7 Million USD 30.77%
1997 Q2 1.1 Million USD 0.0%
1997 Q4 1.62 Million USD 25.22%
1997 Q3 1.3 Million USD 18.18%
1997 FY 5.12 Million USD 337.84%
1997 Q1 1.1 Million USD 92.58%
1996 FY 1.17 Million USD 17.12%
1996 Q4 571.18 Thousand USD 185.59%
1996 Q3 200 Thousand USD 0.0%
1996 Q2 200 Thousand USD 0.0%
1996 Q1 200 Thousand USD -33.33%
1995 Q3 100 Thousand USD -66.67%
1995 Q4 300 Thousand USD 200.0%
1995 FY 1 Million USD 11.11%
1995 Q2 300 Thousand USD 0.0%
1995 Q1 300 Thousand USD -25.0%
1994 FY 900 Thousand USD 800.0%
1994 Q1 100 Thousand USD 0.0%
1994 Q2 200 Thousand USD 100.0%
1994 Q3 200 Thousand USD 0.0%
1994 Q4 400 Thousand USD 100.0%
1993 Q4 - USD -100.0%
1993 Q2 100 Thousand USD 0.0%
1993 Q3 100 Thousand USD 0.0%
1993 FY 100 Thousand USD 0.0%
1993 Q1 100 Thousand USD 0.0%
1992 FY 100 Thousand USD 0.0%
1992 Q3 100 Thousand USD 0.0%
1992 Q4 - USD -100.0%

Peer Revenue Comparison of Navidea Biopharmaceuticals, Inc.

Name Revenue Revenue Difference
America Great Health 204.3 Thousand USD 67.866%
Ampio Pharmaceuticals, Inc. - USD -Infinity%
Aridis Pharmaceuticals, Inc. - USD -Infinity%
Biora Therapeutics, Inc. 4000.00 USD -1541.3%
Bio-Path Holdings, Inc. - USD -Infinity%
Better Therapeutics, Inc. - USD -Infinity%
Calithera Biosciences, Inc. - USD -Infinity%
Comera Life Sciences Holdings, Inc. 633.1 Thousand USD 89.63%
Gene Biotherapeutics, Inc. - USD -Infinity%
eFFECTOR Therapeutics, Inc. - USD -Infinity%
Eloxx Pharmaceuticals, Inc. - USD -Infinity%
Evelo Biosciences, Inc. - USD -Infinity%
Evolutionary Genomics, Inc. - USD -Infinity%
Finch Therapeutics Group, Inc. 107 Thousand USD 38.643%
Galera Therapeutics, Inc. - USD -Infinity%
Innovation1 Biotech Inc. - USD -Infinity%
Kiromic BioPharma, Inc. - USD -Infinity%
Molecular Templates, Inc. 57.3 Million USD 99.885%
NexImmune, Inc. - USD -Infinity%
Orgenesis Inc. 530 Thousand USD 87.613%
Panbela Therapeutics, Inc. - USD -Infinity%
Point of Care Nano-Technology, Inc. - USD -Infinity%
PaxMedica, Inc. Common Stock - USD -Infinity%
Scopus BioPharma Inc. - USD -Infinity%
Sorrento Therapeutics, Inc. 62.83 Million USD 99.896%
Statera Biopharma, Inc. - USD -Infinity%
TRACON Pharmaceuticals, Inc. 12.04 Million USD 99.455%
Trevena, Inc. 3.12 Million USD 97.899%
Vaxxinity, Inc. - USD -Infinity%
Vaccinex, Inc. 570 Thousand USD 88.482%
Vicapsys Life Sciences, Inc. - USD -Infinity%
Viracta Therapeutics, Inc. - USD -Infinity%
ZIVO Bioscience, Inc. 27.65 Thousand USD -137.439%
About
Contact
FAQs